ERα-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches

Chen, Jin‐Qiang; Russo, José

doi:10.1016/j.bbcan.2009.06.003

Cited by 117 publications

(113 citation statements)

References 145 publications

(192 reference statements)

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…Clinically, they are more prevalent in young women and there is some evidence of increased prevalence in African-American women [3]. TNBCs are poorly differentiated, highly malignant, more aggressive and have a poor outcome [9]. They are also characterized by high rate of early recurrence and visceral metastasis [10].…”

Section: Triple Negative Breast Cancersmentioning

confidence: 99%

Curcumin and its derivatives in breast cancer: Current developments and potential for the treatment of drug-resistant cancers

Cridge¹,

Larsen²,

Rosengren³

2013

Oncol Discov

View full text Add to dashboard Cite

Curcumin, a spice found in curry powder, is receiving considerable attention as a possible chemopreventative and chemotherapeutic. This review considers the evidence for the use of curcumin as a treatment for breast cancer, particularly triple negative breast cancers (lacking ER, PR and HER2) which are resistant to many current treatments. Evidence suggests that curcumin suppresses the growth of breast cancers both in vitro and in vivo. In ER-cell lines curcumin causes apoptosis via a range of mechanisms at concentrations ranging between 1 µM and 7.6 µM depending on the cell line and system. In xenograft models, curcumin has been shown to be effective but is limited by its bioavailability. This can be improved by nanotechnologies such as micelles. Studies with micelles have shown that these systems increase the uptake and cytotoxicity of curcumin in vitro. In xenotransplantation models micelles improved bioavailability and increased the half-life of curcumin while showing increases in apoptosis in implanted tumours. The last area discussed is the development of curcumin derivatives. Many of these show increased cytotoxicity (less than 1 µM) and improved pharmacokinetic profiles in vivo. The most potent of these compounds developed to date are RL66 and RL71 with IC 50 values less than 1 µM across a range of breast cancer cell lines, decreased metastasis in a xenograft model, decreased angiogenesis markers and improved tumour growth inhibition as compared to curcumin. Overall, this review concludes that curcumin and its derivatives show future potential as a powerful broad-spectrum treatment for breast cancer.

show abstract

Section: Triple Negative Breast Cancersmentioning

confidence: 99%

Curcumin and its derivatives in breast cancer: Current developments and potential for the treatment of drug-resistant cancers

Cridge¹,

Larsen²,

Rosengren³

2013

Oncol Discov

View full text Add to dashboard Cite

show abstract

“…invasive breast cancer) are usually started on genotoxic therapy without preliminary trials of an estrogens (e.g. tamoxifen) and hercep n, which would very likely be ineffec ve [283].…”

Section: Individual Repair Capacity and Eligibility For Different An mentioning

confidence: 99%

Individual capacity for detoxification of genotoxic compounds and repair of DNA damage. Commonly used methods for assessment of capacity for DNA repair

Chakarov¹,

Petkova²,

Russev³

2014

Biodiscovery

View full text Add to dashboard Cite

The first part of this paper reviews the major achievements in the rapidly expanding field of research of individual capacity for repair of genotoxic damage. The issues of individual repair capacity are addressed from mul ple sides, analyzing the impact of the heritable components of the capacity for detoxifica on of genotoxic compounds, on the one hand (determining the risk for occurrence of DNA damage) and of the capacity for repair of DNA damage (when it has already occurred), on the other hand. The role of the capacity for repair of damage to DNA is discussed in the cons tu on of the risk for development of disease (mainly cancer, but also other common diseases and condi ons, such as diabetes, atherosclerosis and cardiovascular disease) and as a major factor in the outcomes of genotoxic therapies (eligibility for therapy with specific agents, risk for severe adverse effects, post-therapeu c survival rates, etc.). The paper contains an extensive list of biomarkers (mainly DNA polymorphisms, but also enzymes and other phenotypic markers, such as markers of the capacity for self-renewal of cell popula ons) that may be poten ally applicable in the assessment of the risk for carcinogenesis or for development other types of human disease.The second part of the paper provides a brief glimpse of the basic methodology used to obtain experimental results in assessment of the efficiency of DNA repair in living cells for research and diagnos c purposes.Cita on: Chakarov S, Petkova R, Russev GCh. Individual capacity for detoxifica on of genotoxic compounds and repair of DNA damage. Commonly used methods for assessment of capacity for DNA repair.

show abstract

“…invasive breast cancer) are usually started on genotoxic therapy without trials of antiestrogens (e.g. tamoxifen) and herceptin, which would very likely be ineffective (20).…”

Section: Eligibility For Specific Treatment/smentioning

confidence: 99%

What's Your Poison? Impact of Individual Repair Capacity on the Outcomes of Genotoxic Therapies in Cancer. Part I—Role of Individual Repair Capacity in the Constitution of Risk for Late-Onset Multifactorial Disease

Petkova¹,

Chelenkova²,

Georgieva³

et al. 2013

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

ERα-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches

Cited by 117 publications

References 145 publications

Curcumin and its derivatives in breast cancer: Current developments and potential for the treatment of drug-resistant cancers

Curcumin and its derivatives in breast cancer: Current developments and potential for the treatment of drug-resistant cancers

Individual capacity for detoxification of genotoxic compounds and repair of DNA damage. Commonly used methods for assessment of capacity for DNA repair

What's Your Poison? Impact of Individual Repair Capacity on the Outcomes of Genotoxic Therapies in Cancer. Part I—Role of Individual Repair Capacity in the Constitution of Risk for Late-Onset Multifactorial Disease

Contact Info

Product

Resources

About